Altus Pushes Back Phase III Timeline On Lead Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Inconsistencies in a test lot of Altus’ oral pancreatic enzyme insufficiency product deferred one trial; failure of a supplier to deliver critical equipment postponed a trial for its human growth hormone product.